Marlborough, United States
Cognoptix, established in 2019, is making strides in the Biotechnology and Medical Devices sectors with its innovative approach to identifying Alzheimer's disease (AD). The company's slogan, "The Eye Scan for Alzheimer's Early Insight," encapsulates its mission to provide a low-cost, practical, and non-invasive eye scan that detects beta-amyloid deposits in the lens. This biomarker can be identified years before it appears in the brain, offering a revolutionary early detection method for AD.
Headquartered in the United States, Cognoptix last secured a $2.60M Venture Round investment on 28 September 2020. Notable investors include New York Angels, Sidecar Fund2, LaunchPad Venture, and Harvard Business School Alumni Angels of Greater NY. This backing underscores investor confidence in Cognoptix's potential to transform AD diagnosis, presenting a compelling opportunity for stakeholders in Health Care and Health and Wellness.
